Liquisolid systems and aspects influencing their research and development

Open access


Many modern drugs are poorly water soluble substances, which causes difficulties in the development of solid dosage forms with sufficient bioavailability. Preparation of liquisolid systems (LSS) is a novel technique for improving solubility, dissolution and bioavailability of such drugs. The basic principle of LSS preparation is conversion of the drug in liquid state into a free-flowing, compressible, dry powder through its absorption into suitable excipients - porous carriers (aluminometasilicates, microcrystalline cellulose), subsequently coated with material having high absorption capacity (silicon dioxide commonly known as colloidal silica). LSS exhibit advantages such as lower production costs compared to soft capsules, simple processing and enhanced drug release. The main benefit is higher bioavailability of the liquid drug, caused by a large surface area available for absorption. The article tries to clarify specific aspects connected with the formulation of LSS: properties of excipients (surface area, absorption capacity), variables related to the processing (solubility, liquid load factor) and dosage form evaluation.

  • 1. M. Yazdanian, K. Briggs, C. Jankovsky and A. Hawi, The »high solubility« definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs, Pharm. Res. 21 (2004) 293-299; DOI: 10.1023/B:PHAM.0000016242.48642.71.

  • 2. L. X. Yu, G. L. Amidon, J. E. Polli, H. Zhao, M. U. Mehta, D. P. Conner, V. P. Shah, L. J. Lesko, M. Chen, V. H. L. Lee and A. S. Hussain, Biopharmaceutics classification system: The scientific basis for biowaiver extensions, Pharm. Res. 19 (2002) 921-925; DOI: 10.1023/A:1016473601633.

  • 3. A. V. Yadav, A. S. Shete and A. P. Dabke, Formulation and evaluation of orodispersible liquisolid compacts of aceclofenac, Ind. J. Pharm. Educ. 44 (2010) 227-235.

  • 4. Y. Javadzadeh, M. R. Siahi, S. Asnaashari and A. Nokhodchi, Liquisolid technique as a tool for enhancement of poorly water-soluble drugs and evaluation of their physicochemical properties, Acta Pharm. 57 (2007) 99-109; DOI: 10.2478/v10007-007-0008-6.

  • 5. S. Nazzal and M. A. Khan, Controlled release of a self-emulsifying formulation from a tablet dosage form: Stability assessment and optimization of some processing parameters, Int. J. Pharm. 315 (2006) 110-121; DOI: 10.1016/j.ijpharm.2006.02.019.

  • 6. N. Rasenack and B. W. Müller, Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs, Pharm. Res. 19 (2002) 1894-1900; DOI: 10.1023/A:1021410028371.

  • 7. A. B. Nighute and S. B. Bhise, Enhancement of dissolution rate of Rifabutin by preparation of microcrystals using solvent change method, Int. J. Pharm. Tech. Res. 1 (2009) 142-148.

  • 8. G. V. Betager and K. R. Makarla, Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques, Int. J. Pharm. 126 (1995) 155-160; DOI: 10.1016/0378-5173(95) 04114-1.

  • 9. J. W. Millard, F. A. Alvarez-Núñez and S. H. Yalkowsky Solubilization by cosolvents establishing useful constants for the log-linear model, Int. J. Pharm. 245 (2002) 153-166; DOI: 10.1016/ S0378-5173(02)00334-4.

  • 10. P. Balakrishnan, B. Le, D. H. Oh, J. O. Kim, M. J. Hong, J. Jee, J. A. Kim, B. K. Yoo, J. S. Woo, C. S. Yong and H. Choi, Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS), Eur. J. Pharm. Biopharm. 72 (2009) 539-545; DOI: 10.1016/j. ejpb.2009.03.001.

  • 11. A. Zvonar, K. Berginc, A. Kristl and M. Ga{perlin, Microencapsulation of self-microemulsifying system: Improving solubility and permeability of furosemide, Int. J. Pharm. 388 (2010) 151-158; DOI: 10.1016/j.ijpharm.2009.12.055.

  • 12. H. A. Hassan, A. H. Al-Marzouqi, B. Jobe, A. A. Hamza and G. A. Ramadan, Enhancement of dissolution amount and in vivo bioavailability of itraconazole by complexation with b-cyclodextrin using supercritical carbon dioxide, J. Pharmaceut. Biomed. 45 (2007) 243-250; DOI: 10.1016/j.jpba.2007.06.011.

  • 13. T. Tanino, T. Ogiso, M. Iwaki, G. Tanabe and O. Muraoka, Enhancement of oral bioavailability of phenytoin by esterification, and in vitro hydrolytic characteristics of prodrugs, Int. J. Pharm. 163 (1998) 91-102; DOI: 10.1016/S0378-5173(97)00374-8.

  • 14. S. G. Kapsi and J. W. Ayres, Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability, Int. J. Pharm. 229(2001) 193-203; DOI: 10.1016/S0378-5173(01)00867-5.

  • 15. D. X. Li, Y. Oh, S. Lim, J. O. Kim, H. J. Yang, J. H. Sung, C. S. Yong and H. Choi, Novel gelatin microcapsule with bioavailability enhancement of ibuprofen using spray-drying technique, Int.J. Pharm. 355 (2008) 277-284; DOI: 10.1016/j.ijpharm.2007.12.020.

  • 16. V. Stella, J. Haslam, N. Yata, H. Okada, S. Lindenbaum and T. Higuchi, Enhancement of bioavailability of a hydrophobic amine antimalarial by formulation with oleic acid in a soft gelatin capsule, J. Pharm. Sci. 67 (1978) 1375-1377.

  • 17. V. K. Nagabandi, T. Ramarao and K. N. Jayaveera, Liquisolid compacts: A novel approach to enhance bioavailability of poorly soluble drugs, Int. J. Pharm. Biol. Sci. 1 (2011) 89-102.

  • 18. N. Tiong and A. A. Elkordy, Effects of liquisolid formulations on dissolution of naproxen, Eur. J. Pharm. Biopharm. 73 (2009) 373-384; DOI: 10.1016/j.ejpb.2009.08.002.

  • 19. K. Kavitha, K. N. S. LovaRaju, N. S. Ganesh and B. Ramesh, Effect of dissolution rate by liquisolid compacts approach: An overview, Der Pharmacia Lettre 3 (2011) 71-83.

  • 20. A. S. Kulkarni, N. H. Aloorkar, M. S. Mane and J. B. Gaja, Liquisolid systems: a review, Int. J. Pharm. Sci. Nanotechnol. 3 (2010) 795-802.

  • 21. S. M. Gavali, S. S. Pacharane, S. V. Sankpal, K. R. Jadhav and V. J. Kadam, Liquisolid compact: A new technique for enhancement of drug dissolution, Int. J. Res. Pharm. Chem. 1 (2011) 705-713.

  • 22. A. B. Karmarkar, I. D. Gonjari, A. H. Hosmani, P. N. Dhabale and S. B. Bhise, Liquisolid tablets: A novel approach for drug delivery, Int. J. Health Res. 2 (2009) 45-50.

  • 23. A. B. Karmarkar, I. D. Gonjari and A. H. Hosmani, Liquisolid technology for dissolution rate enhancement or sustained release, Expert Opin. Drug Deliv. 7 (2010) 1227-1234; DOI: 10.1517/17425247.2010.511173.

  • 24. M. El-Hammadi and N. Awad, Investigating the use of liquisolid compacts technique to minimize the influence of pH variations on loratadine release, AAPSPharmSciTech. 13 (2012) 53-58; DOI: 10.1208/s12249-011-9719-6.

  • 25. A. K. Elkhodairy and M. W. Samy, Optimization and evaluation of micromeritic and release properties of high dose flutamide liquisolid systems, Lett. Drug Des. Discov. 9 (2012) 336-344; DOI: 10.2174/157018012799129873.

  • 26. Y. Javadzadeh, B. Jafari-Navimipour and A. Nokhodchi, Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine), Int. J. Pharm. 341 (2007) 26-34; DOI: 10.1016/j.ijpharm.2007.03.034.

  • 27. S. K. Singh, K. K. Srinivasan, K. Gowthamarajan, D. Prakash, N. B. Gaikwad and D. S. Singare, Influence of formulation parameters on dissolution rate enhancement of glyburide using liquisolid technique, Drug Dev. Ind. Pharm. 38 (2012) 961-970; DOI: 10.3109/03639045.2011.634810.

  • 28. C. M. Hentzschel, A. Sakmann and C. S. Leopold, Suitability of various excipients as carrier and coating materials for liquisolid compacts, Drug Dev. Ind. Pharm. 37 (2011) 1200-1207; DOI: 10.3109/03639045.2011.564184.

  • 29. B. M. El-Houssieny, L. F. Wahman and N. M. Arafa, Bioavailability and biological activity of liquisolid compact formula of repaglinide and its effect on glucose tolerance in rabbits, Biosci.Trends. 4 (2010) 17-24.

  • 30. K. A. Khaled, Y. A. Asiri and Y. M. El-Sayed, In vivo evaluation of hydrochlorothiazide liquisolid tablets in beagle dogs, Int. J. Pharm. 222 (2001) 1-6; DOI: 10.1016/S0378-5173(01)00633-0.

  • 31. B. Chen, Z. Wang, G. Quan, X. Peng, X. Pan, R. Wang, Y. XU, G. Li and C. Wu, In vitro and in vivo evaluation of ordered mesoporous silica as a novel adsorbent in liquisolid formulation, Int. J. Nanomed. 7 (2012) 199-209; DOI: 10.2147/IJN.S26763.

  • 32. R. H. Fahmy and M. A. Kassem, Enhancement of famotidine dissolution rate through liquisolid tablets formulation: In vitro and in vivo evaluation, Eur. J. Pharm. Biopharm. 69(2008) 993-1003; DOI: 10.1016/j.ejpb.2008.02.017.

  • 33. I. D. Gonjari, A. B. Karmarkar and A. H. Hosmani, Evaluation of in vitro dissolution profile comparison methods of sustained release tramadol hydrochloride liquisolid compact formulations with marketed sustained release tablets, Dig. J. Nanomater. Bios. 4 (2009) 651-661.

  • 34. H. S. Mahajan, M. R. Dhamne, S. G. Gattani, A. D. Rasal and H. T. Shaikh, Enhanced dissolution rate of glipizide by a liquisolid technique, Int. J. Pharm. Sci. Nanotech. 3 (2011) 1205-1213.

  • 35. Y. Javadzadeh, L. Musaalrezaei and A. Nokhodchi, Liquisolid technique as a new approach to sustain propranolol hydrochloride release from tablet matrices, Int. J. Pharm. 362 (2008) 102-108; DOI: 10.1016/j.ijpharm.2008.06.022.

  • 36. A. Nokhodchi, R. Aliakbar, S. Desai and Y. Javadzadeh, Liquisolid compacts: The effect of cosolvent and HPMC in theophylline release, Colloid Surface B. 79 (2010) 262-269; DOI: 10.1016/j. colsurfb.2010.04.008.

  • 37. Center for the Evaluation of Risks to Human Reproduction, NTP-CERHR Expert Panel report on the reproductive and developmental toxicity of propylene glycol, Reprod. Toxicol. 18 (2004) 533-579; DOI: 10.1016/j.reprotox.2004.01.004.

  • 38. Cefic, Propylene Glycol - Pharmaceuticals, n.d.;, access date January 17, 2012.

  • 39. S. Gubbi and R. Jarag, Liquisolid Technique for enhancement of dissolution properties of bromhexine hydrochloride, Res. J. Pharm. Tech. 2 (2009) 382-386.

  • 40. BASF group, Lutrol® E Liquid Grades, 2010;; access date January 18, 2012.

  • 41. R. C. Rowe, P. J. Sheskey and S. C. Owen, Handbook of Pharmaceutical Excipients, 5th ed., Pharmaceutical Press, London 2006, p. 918.

  • 42. C. F. Daher, G. M. Baroody and R. J. Howland, Effect of a surfactant, Tween 80, on the formation and secretion of chylomicrons in the rat, Food Chem. Toxicol. 41 (2003) 575-582; DOI: 10.1016/ S0278-6915(02)00299-5.

  • 43. T. Tatsuishi, Y. Oyama, K. Iwase, J. Y. Yamaguchi, M. Kobayashi, Y. Nishimura, A. Kanada and S. Hirama, Polysorbate 80 increases the susceptibility to oxidative stress in rat thymocytes, Toxicology 207 (2005) 7-14; DOI: 10.1016/j.tox.2004.07.020.

  • 44. W. Wang, Y. J. Wang and D. Q. Wang, Dual effect of Tween 80 on protein stability, Int. J. Pharm. 347 (2008) 31-38; DOI: 10.1016/j.ijpharm.2007.06.042.

  • 45. S. A. Tayel, I. I. Soliman and D. Louis, Improvement of dissolution properties of carbamazepine through application of the liquisolid tablet technique, Eur. J. Pharm. Biopharm. 69 (2008) 342-347; DOI: 10.1016/j.ejpb.2007.09.003.

  • 46. M. Saeedi, J. Akbari, K. Morteza-Semnani, R. Enayati-Fard, S.Sar-Reshteh-dar and A. Soleymani, Enhancement of dissolution rate of indomethacin using liquisolid compacts, Iran J. Pharm.Res. 10 (2011) 25-34.

  • 47. V. B. Yadav and A. V. Yadav, Improvement of solubility and dissolution of indomethacin by liquisolid and compaction granulation technique, J. Pharm. Sci. Res. 1 (2009) 44-51.

  • 48. Y. Javadzadeh, M. R. Siahi-Shadbad, M. Barzegar-Jalali and A. Nokhodchi, Enhancement of dissolution rate of piroxicam using liquisolid compacts, Il Farmaco 60 (2005) 361-365; DOI: 10. 1016/j.farmac.2004.09.005.

  • 49. A. A. Elkordy, U. Bhangale, N. Murle and M. F. Zarara, Combination of lactose (as a carrier) with Cremophor® EL (as a liquid vehicle) to enhance dissolution of griseofulvin, Powder Technol. 246 (2013) 182-186; DOI: 10.1016/j.powtec.2013.05.024.

  • 50. B. Akinlade, A. A. Elkordy, E. A. Essa and S. Elhagar, Liquisolid systems to improve the dissolution of furosemide, Sci. Pharm. 78 (2010) 325-344; DOI: 10.3797/scipharm.0912-23.

  • 51. C. C. Liao and C. I. Jarowski, Dissolution rates of corticoid solutions dispersed on silicas, J. Pharm.Sci. 73 (1984) 401-403; DOI: 10.1002/jps.2600730330.

  • 52. A. A. Elkordy, X. N. Tan and E. A. Essa, Spironolactone release from liquisolid formulations prepared with CapryolTM 90, Solutol® HS-15 and Kollicoat® SR 30 D as non-volatile liquid vehicles, Eur. J. Pharm. Biopharm. 83 (2013) 203-223; DOI: 10.1016/j.ejpb.2012.08.004.

  • 53. A. A. Elkordy, E. A. Essa, S. Dhuppad and P. Jammiqumpula, Liquisolid technique to enhance and to sustain griseofulvin dissolution: effect of choice of non-volatile liquid vehicles, Int. J. Pharm. 434 (2012) 122-132; DOI: 10.1016/j.ijpharm.2012.05.072.

  • 54. V. Agarwal, A. Siddiqui, H. Ali and S. Nazzal, Dissolution and power flow characterization of solid self-emulsified drug delivery system (SEDDS), Int. J. Pharm. 366 (2009) 44-52; DOI: 10. 1016/j.ijpharm.2008.08.046.

  • 55. G. Kahr and F. T. Madsen, Determination of the cation exchange capacity and the surface area of bentonite, illite and kaolinite by methylene blue absorption, Appl. Clay Sci. 9 (1995) 327-336; DOI: 10.1016/0169-1317(94)00028-O.

  • 56. M. Van Speybroeck, R. Mellaerts, R. Mols, T. D. Thi, J. A. Martens, J. Van Humbeeck, P. Annaert, G. Van den Mooter and P. Augistijns, Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica, Eur. J. Pharm. Sci. 41 (2010) 623-630; DOI: 10.1016/j.ejps.2010.09.002.

  • 57. V. B. Yadav, A. B. Nighute, A. V. Yadav and S. B. Bhise, Aceclofenac size enlargement by non- -aqueous granulation with improved solubility and dissolution, Arch. Pharm. Sci. Res. 1 (2009) 115-122.

  • 58. P. G. Manogar, B. N. V. Hari and D. R. Devi, Emerging liquisolid compact technology for solubility enhancement of BCS Class-II drug, J. Pharm. Sci. Res. 3 (2011) 1604-1611.

  • 59. Fuji Chemical Industry Co., Ltd., Neusilin - Generel Properties, 2010;; access date October 18, 2012.

  • 60. C. M. Hentzschel, M. Alnaief, I. Smirnova, A. Sakmann and C. S. Leopold, Tableting properties of silica aerogels and other silicates, Drug Dev. Ind. Pharm. 38 (2012) 462-467; DOI: 10.3109/03639045.2011.611806.

  • 61. Fuji Chemical Industry Co., Ltd., Neusilin, 2011; medicine/neusilin/index.html; access date October 18, 2012.

  • 62. Fuji Chemical Industry Co., Ltd., The Specialty Excipient Neusilin®, 2009; http://www.harke. com/fileadmin/images/pharma/Broschueren/Fuji_Neusilin.pdf; access date January 18, 2012.

  • 63. X. Zhao, Y. Q. Zhou, S. Potharaju, H. Lou, H. M. Sun, E. Brunson, H. Almoazen and J. Johnson, Development of a self micro-emulsifying tablet of cyclosporine-A by the liquisolid compact technique, Int. J. Pharm. Sci. Res. 2 (2011) 2299-2308.

  • 64. B. Van Eerdenbrugh, L. Froyen, J. Van Humbeeck, J. A. Martens, P. Augustijns and G. Van Den Mooter, Alternative matrix formers for nanosupension solidification: Dissolution performance and X-ray microanalysis as an evaluation tool for powder dispersion, Eur. J. Pharm. Sci. 35 (2008) 344-353; DOI: 10.1016/j.ejps.2008.08.003.

  • 65. M. J. Kang, S. Y. Jung, W. H. Song, J. S. Park, S. U. Choi, K. T. Oh, H. K. Choi, Y. W. Choi, J. Lee, B. J. Lee and S. C. Chi, Immediate release of ibuprofen from Fujicalin®-based fast-dissolving self-emulsifying tablets, Drug Dev. Ind. Pharm. 37 (2011) 1298-1305; DOI:10.3109/03639045.2011.571695.

  • 66. H. Schlack, A. Bauer-Brandl, R. Schubert and D. Becker, Properties of Fujicalin®, A new modified anhydrous dibasic calcium phosphate for direct compression: Comparison with dicalcium phosphate dihydrate, Drug Dev. Ind. Pharm. 27 (2001) 789-801.

  • 67. Z. Wu, Y. Jiang, T. Kim and K. Lee, Effect of surface coating on the controlled release of vitamin B1 from mesoporous silica tablets, J. Control. Release 119 (2007) 215-221; DOI: 10.1016/j.jconrel. 2007.03.001.

  • 68. T. Ukmar and O. Planin{ek, Ordered mesoporous silicates as matrices for controlled release of drugs, Acta Pharm. 60 (2010) 373-385; DOI: 10.2478/v1007-010-0037-4.

  • 69. M. Vallet-Regi, A. Ramila, R. P. del Rea and J. Pérez-Pariente, A new property of MCM-41: drug delivery system, Chem. Mater. 13 (2001) 308-311; DOI: 10.1021/cm0011559.70. R. Mellaerts, R. Mois, J. A. G. Jammaer, C. A. Aerts, P. Annaert, J. Van Humbeeck, G. Van den Mooter, P. Augustijns and J. A. Martens, Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica, Eur. J. Pharm. Biopharm. 69 (2008) 223-230; DOI: 10.1016/j.ejpb.2007.11.006.

  • 71. M. Vialpando, F. Backhuijs, J. A. Martens and G. Van den Mooter, Risk assessment of premature drug release during wet granulation of ordered mesoporous silica loaded with poorly soluble compounds intraconazole, fenofibrate, naproxen, and ibuprofen, Eur. J. Pharm. Biopharm. 81 (2012) 190-198; DOI: 10.1016/j.ejpb.2012.01.012.

  • 72. T. Heikkilä, J. Salonen, J. Tuura, N. Kumar, T. Salmi, D. Y. Murzin, M. S. Hamdy, G. Mul, L. Laitinen, A. M. Kaukonen, J. Hirvonen and V. P. Lehto, Evaluation of mesoporous TCPSi, MCM-41, SBA-15 and TUD-1 materials as API carriers for oral drug delivery, Drug Deliv. 14 (2007) 337-347; DOI: 10.1080/10717540601098823.

  • 73. M. Van Speybroeck, V. Barillaro, T. D. Thi, R. Mellaerts, J. Martens, J. Van Humbeeck, J. Vermant, P. Annaert, G. Van den Mooter and P. Augustijns, Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs, J. Pharm. Sci. 98 (2009) 2648-2658; DOI: 10.1002/jps.21638.

  • 74. B. Chen, G. Quan, Z. Wang, J. Chen, L. Wu, Y. Xu, G. Li and C. Wu, Hollow mesoporoussilicas as a drug solution delivery system for insoluble drugs, Powder Technol. 240 (2013) 48-53; DOI: 10.1016/j.powtec.2012.07.008.

  • 75. S. R. Gubbi and R. Jarag, Formulation and characterization of atorvastatin calcium liquisolid compacts, Asian J. Pharm. Sci. 5 (2010) 50-60.

  • 76. K. M. El-Say, A. M. Samy and M. I. Fetouh, Formulation and evaluation of rofecoxib liquisolid tablets, Int. J. Pharm. Sci. Rev. Res. 3 (2010) 135-142.

  • 77. A. Krupa, D. Majda, R. Jachowicz and W. Mozgawa, Solid-state interaction of ibuprofen and Neusilin US2, Thermochim. Acta 509 (2010) 12-17; DOI: 10.1016/j.tca.2010.05.009.

  • 78. A. Sheth and C. I. Jarowski, Use of powdered solutions to improve the dissolution rate of polythiazide tablets, Drug Dev. Ind. Pharm. 16 (1990) 769-777; DOI: 10.3109/03639049009114908.

  • 79. E. B. Basalious, W. El-Sebaie and O. El-Gazayerly, Rapidly absorbed orodispersible tablet containing molecularly dispersed felodipine for management of hypertensive crisis: Development, optimization and in vitro/in vivo studies, Pharm. Dev. Technol. 18 (2013) 407-416; DOI: 10.3109/

  • 10837450.2012.659258.

  • 80. S. S. Spireas, C. I. Jarowski and B. D. Rohera, Powdered solution technology: Principles and mechanism, Pharm. Res. 9 (1992) 1351-1358; DOI: 10.1023/A:1015877905988.

  • 81. M. Khanfar, S. M. Sheikh and R. Hawari, Formulation factors affecting the release of ezetimibe from different liquisolid compacts, Pharm. Dev. Technol. 18 (2013) 417-427; DOI: 10.3109/10837450.2012.680594.

  • 82. S. Spireas and S. M. Bolton, Liquisolid Systems and Methods of Preparing Same, US 5,968,550, 19 October 1999.

  • 83. S. Spireas and S. M. Bolton SM, Liquisolid Systems and Methods of Preparing Same, US 6,423,339, 23 July 2002.

  • 84. K. Rajesh, R. Rajalakshmi, J. Umamaheswari and C. K. A. Kumar, Liquisolid technique: a novel approach to enhance solubility and bioavailability, Int. J. Biopharm. 2 (2011) 8-13.

  • 85. R.Grover, S. Spireas and C. Lau-Cam, Development of a simple spectrophotometric method for propylene glycol detection in tablets, J. Pharm. Biomed. Anal. 16 (1998) 931-938; DOI: 10.1016/ S0731-7085(97)00098-8.

  • 86. R. Boghra, A. Patel, H. Desai and A. Jadhav, Formulation and evaluation of irbesartan liquisolid tablets, Int. J. Pharm. Sci. Rev. Res. 9 (2011) 32-37.

  • 87. S. V. Kasture, S. B. Gondkar, A. B. Darekar, D. Priyobrata and K. V. Bhambar, Enhancement of dissolution rate of lansoprazole using liquisolid tablet technique, Int. J. Pharm. Res. 3 (2011) 27-31.

  • 88. M. A. Hassan and H. M. El-Saghir, Enhancement of dissolution and the anti-inflammatory effect of nimesulide, using liquisolid compact for oral appliccation, Bull. Pharm. Sci. 34 (2011) 1-8.

  • 89. The European Directorate for the Quality of Medicines & Health Care, European Pharmacopoeia 7.2, 2011;; access date February 18, 2012.

  • 90. D. C. Bibby, N. M. Davies and I. G. Tucker, Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems, Int. J. Pharm. 197 (2000) 1-11; DOI: 10.1016/S0378-5173(00)00335-5.

  • 91. D. Q. Craig, The mechanisms of drug release from solid dispersions in water-soluble polymers, Int. J. Pharm. 231 (2002) 131-144; DOI: 10.1016/S0378-5173(01)00891-2.

  • 92. A. Nokhodchi, C. M. Hentzschel and C. S. Leopold, Drug release from liquisolid systems: speed it up, slow it down, Expert Opin. Drug Deliv. 8 (2011) 191-205; DOI: 10.1517/17425247.2011.548801.

  • 93. A. Panda and D. M. Biyani, Studies on liquisolid system as a technique to modify the dissolution rate of nefedipine, Am. J. Pharmtech. Res. 3 (2013) 686-698.

  • 94. N. Chella, N. Shastri and R. R. Tadikonda, Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan, Acta Pharm. Sin B. 2 (2012) 502-508; DOI: 10.1016/j. apsb.2012.07.005..

  • 95. N. Thakur, S. L. Khokra, D. Sharma, N. S. Thakur, R. Purohit and V. Arya, A review on pharmaceutical application of liquisolid technique, Am. J. Pharmtech. Res. 1 (2011) 1-18.

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

Journal Information

IMPACT FACTOR 2016: 1.288
5-year IMPACT FACTOR: 1.600

CiteScore 2016: 1.55

SCImago Journal Rank (SJR) 2016: 0.353
Source Normalized Impact per Paper (SNIP) 2016: 0.854


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 12 12 12
PDF Downloads 1 1 1